Rappta Therapeutics is a late preclinical stage biopharmaceutical company focused on developing first-in-class anti-cancer molecular glues that reactivate the tumor suppressor protein phosphatase 2A (PP2A)
Rappta Therapeutics is a late preclinical stage biopharmaceutical company focused on developing first-in-class anti-cancer molecular glues that reactivate the tumor suppressor protein phosphatase 2A (PP2A). Their proprietary technology aims to therapeutically reactivate PP2A, which plays a critical role in regulating protein de-phosphorylation and tumor growth, with potential applications across a range of human diseases.